TY - JOUR ID - 47884 TI - Co-Administration of Vitamin E and Atorvastatin Improves Insulin Sensitivity and Peroxisome Proliferator-Activated Receptor-γ Expression in Type 2 Diabetic Patients: A Randomized Double-Blind Clinical Trial JO - Iranian Journal of Medical Sciences JA - IJMS LA - en SN - 0253-0716 AU - Tabaei, Banafsheh Sadat AU - Mousavi, Seyedeh Neda AU - Rahimian, Aliasghar AU - Rostamkhani, Hadi AU - Mellati, Ali Awsat AU - Jameshorani, Maryam AD - Zanjan Metabolic Diseases Research Center, Zanjan University of Medical Sciences, Zanjan, Iran AD - Department of Clinical Biochemistry, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran AD - Department of Clinical Biochemistry, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran Y1 - 2022 PY - 2022 VL - 47 IS - 2 SP - 114 EP - 122 KW - Atorvastatin KW - diabetes mellitus KW - Insulin Resistance KW - Peroxisome proliferator-activated receptors KW - Vitamin E DO - 10.30476/ijms.2021.89102.1981 N2 - Background: Negative effects of statins on glucose metabolism have been reported. The present study aimed to investigate the effects of co-administration of vitamin E and atorvastatin on glycemic control in hyperlipidemic patients with type 2 diabetes mellitus (T2DM). Methods: A randomized double-blind clinical trial was conducted at Vali-e-Asr Teaching Hospital (Zanjan, Iran) from July 2017 to March 2018. A total of 30 T2DM female patients were allocated to two groups, namely atorvastatin with placebo (n=15) and atorvastatin with vitamin E (n=15). The patients received daily 20 mg atorvastatin and 400 IU vitamin E or placebo for 12 weeks. Anthropometric and biochemical measures were recorded pre- and post-intervention. Peroxisome proliferator-activated receptor-γ (PPAR-γ) expression was measured in peripheral blood mononuclear cells (PBMCs). Independent sample t test and paired t test were used to analyze between- and within-group variables, respectively. The analysis of covariance (ANCOVA) was used to adjust the effect of baseline variables on the outcomes. p Results: After baseline adjustment, there was a significant improvement in homeostatic model assessment for insulin resistance (HOMA-IR) (P=0.04) and serum insulin (p <0.001) in the atorvastatin with vitamin E group compared to the atorvastatin with the placebo group. In addition, co-administration of vitamin E with atorvastatin significantly upregulated PPAR-γ expression (OR=5.4, P=0.04) in the PBMCs of T2DM patients. Conclusion: Co-administration of vitamin E and atorvastatin reduced insulin resistance and improved PPAR-γ mRNA expression. Further studies are required to substantiate our findings.Trial registration number: IRCT 20170918036256N1 UR - https://ijms.sums.ac.ir/article_47884.html L1 - https://ijms.sums.ac.ir/article_47884_c32d1a52aa9b39e653e06ecef77f44f7.pdf ER -